Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation.

Authors : Henningsen Kristoffer Mads KM; Nilsson Brian B; Johansen Julia S JS; Chen Xu X; Pehrson Steen S; Svendsen Jesper Hastrup JH;

Affiliations : Department of Cardiology, Cardiac Catheterization Laboratory 2014, The Heart Centre, Rigshospitalet, University of Copenhagen, 2100, Copenhagen Ø, Denmark, Kristofferh@webspeed.dk.

Journal : N/A   (2009)

Related Links: Pubmed | Publisher website

Increased NT-pro-B-type natriuretic peptide independently predicts outcome following catheter ablation of atrial fibrillation.

Authors : Nilsson Brian B; Goetze Jens Peter JP; Chen Xu X; Pehrson Steen S; Svendsen Jesper Hastrup JH;

Affiliations : Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen. brni@dadlnet.dk

Journal : Scand. J. Clin. Lab. Invest.   (2009)

Related Links: Pubmed | Publisher website

"Percutaneous atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review

Authors :

Affiliations : "Correspondence to Tristan D. Yan, MBBS, MD, PhD The Systematic Review Group, The Baird Institute for Applied Heart and Lung Surgical Research, Sydney, Australia. tristanyan@annalscts.com "

Journal : Original article   (2012)

Related Links: Pubmed | Publisher website

Percutaneous atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review

Authors :

Affiliations : The University of Copenhagen, Copenhagen, Denmark The Systematic Review Group, The Baird Institute for Applied Heart and Lung Surgical Research, Sydney, Australia Department of Cardiology, Rigshospitalet, Copenhagen, Denmark Hvidovre University Hospital, Copenhagen, Denmark

Journal : N/A   (2012)

Related Links: Pubmed | Publisher website

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition a

Authors : Daniel Lindholm, MD; Agneta Siegbahn, MD, PhD; Lisa Wernroth, MSc; Richard C. Becker, MD; Christopher P. Cannon, MD; Jan H. Cornel, MD, PhD; Anders Himmelmann, MD, PhD; Evangelos Giannitsis, MD; Robert A. Harrington, MD; Claes Held, MD, PhD; Steen Husted, MD, DSc; Hugo A. Katus, MD; Kenneth W. Mahaffey, MD; Ph. Gabriel Steg, MD; Robert F. Storey, MD, DM; Stefan K. James, MD, PhD;

Affiliations : Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (L.W., D.L., L.W., C.H., S.K.J.); Department of Medical Sciences, Clinical Chemistry and Uppsala Clinical Research Center Uppsala University, Uppsala, Sweden (A.S.); Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, Academic Health Center, Cincinnati, OH (R.C.B.); Department of Medicine, Stanford University, Stanford, CA (R.A.H., K.W.M.); TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (C.P.C.); Department of Cardiology, Medisch Centrum Alkmaar, Alkmaar, Netherlands (J.H.C.); AstraZeneca Research and Development, Mölndal, Sweden (A.H.); Medizinische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany (E.G., H.A.K.); Medical Department, Hospital Unit West, Herning/Holstbro, Denmark (S.H.); INSERM-Unité 698, Paris, France; Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France; Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France; NHLI Imperial College, ICMS, Royal Brompton Hospital, London, UK (P.G.S.); and Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.).

Journal : N/A   (2014)

Related Links: Pubmed | Publisher website